Safety and Efficacy Study of Dysport RU and Glabellar Lines
A Phase II, Double Blind, Randomised, Placebo and Active Comparator Controlled Study to Assess the Safety and Efficacy of Three Doses of Dysport RU (20 U, 50 U, and 75 U) Administered as a Single Treatment Cycle to Improve the Appearance of Moderate to Severe Glabellar Lines
Sponsor: Ipsen
Listed as NCT01333397, this PHASE2 trial focuses on Glabellar Frown Lines and remains completed. Sponsored by Ipsen, it has been updated 8 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Sep 2022 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Sep 2019 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Sep 2019 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Mar 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ipsen
For direct contact, visit the study record on ClinicalTrials.gov .